SSC 2026 Guidelines now available — 129 adult & 61 pediatric recommendations View guidelines →
Clinical reference for vascular access in special populations: pediatric, NICU/neonatal, oncology, hemodialysis, critical care, geriatric, obese, and immunocompromised patients — device selection, technique modifications, and population-specific risks.
Standard vascular access approaches must be adapted for populations with anatomically, physiologically, or clinically distinct characteristics. Pediatric patients have smaller, more fragile veins and unique developmental considerations. Neonates require specialized devices for umbilical access. Oncology patients need durable central access for chemotherapy while managing heightened infection risk. Hemodialysis patients depend on a hierarchy of access modalities with distinct nursing management. Critical care patients require simultaneous hemodynamic monitoring access alongside therapeutic infusion.
This guide covers the most clinically significant special population scenarios for vascular access, with device selection guidance, technique considerations, and population-specific risk management.
Vascular access in children is challenging for multiple reasons:
| Age | Preferred PIV Sites |
|---|---|
| Neonate/infant | Dorsum of hand, forefoot, scalp veins (anterior temporal, frontal, occipital), antecubital |
| Toddler (1–3 yr) | Dorsum of hand, forearm, antecubital; avoid feet if ambulatory |
| Preschool (3–6 yr) | Forearm, antecubital, dorsum of hand |
| School-age+ | Forearm, antecubital, dorsum of hand (same as adult); avoid dominant hand if possible |
Scalp vein IVs in neonates and infants:
Pain management is a clinical and ethical obligation during pediatric IV procedures:
Pediatric PICC indications are similar to adult but with age-specific device sizing. Key considerations:
The NICU patient population presents the most technically demanding and highest-stakes vascular access challenges in clinical practice. Premature neonates have fragile, microscopic vessels, immature skin, and physiologic vulnerabilities that amplify the consequences of every catheter complication.
The UVC is inserted through the umbilical vein, which remains patent and accessible in the first 3–5 days of life.
Indications:
Tip position: Lower IVC, at the junction of the IVC and right atrium (above the diaphragm and hepatic veins). A tip in the hepatic circulation risks hepatic necrosis from concentrated infusates; confirm position by CXR.
Dwell time: Maximum 7–14 days per most NICU protocols (infection risk increases significantly after 14 days).
The UAC accesses the umbilical artery (paired vessels in the umbilical cord) for continuous blood pressure monitoring and arterial blood gas sampling.
Tip position: Either “high” (T6–T9, above the celiac axis) or “low” (L3–L5, below the renal and mesenteric arteries). High position is more commonly used.
Dwell time: Maximum 5–7 days in most NICU protocols.
NICU PICCs (often called “long-lines”) are placed via peripheral veins (basilic, saphenous, great saphenous, scalp) and advanced to the SVC/CAJ.
NICU PICC indications: PN >5 days, IV access needed beyond the first week of life, home IV therapy in stable infants being discharged.
Complications: NICU PICC-associated CLABSI is a critical quality metric; NICU CLABSI rates are tracked by NHSN and benchmarked by birth weight strata. PICC-associated cardiac tamponade (from tip in the right atrium) is a rare but catastrophic neonatal complication — confirm tip is not in the heart.
Cancer patients represent one of the most complex vascular access populations, with competing considerations of high-volume chemotherapy, infection risk from immunosuppression, the need for durable access for long-term or intermittent therapy, and the importance of patient comfort and autonomy.
| Feature | Implanted Port | PICC |
|---|---|---|
| Dwell | Years (the device; needle changed per access) | Weeks to months |
| Body image | No external device between accesses | External device visible/palpable |
| Infection risk | Low (completely subcutaneous) | Moderate (external exit site) |
| Maintenance between accesses | Monthly flush (inactive periods) | Weekly dressing + flush |
| Access | Requires Huber needle (ANTT, some discomfort) | External hub; easier access |
| Best for | Long-term/intermittent chemotherapy, long-term PN, repeated IV access | Short- to medium-term infusion, OPAT, bridge access |
| CVAA/AVAR preference | Port preferred for >3 months intermittent therapy | PICC appropriate for continuous or short-term therapy |
ONS/ASCO recommendations: Implanted ports are preferred for most long-term and intermittent chemotherapy protocols. PICCs are appropriate for continuous infusions (e.g., continuous 5-FU), OPAT, and patients who are not candidates for port placement.
All vesicant chemotherapy agents must be administered through a confirmed, functional central venous access device. Pre-administration assessment must confirm: brisk blood return, easy flushing, no swelling or pain at infusion site. For peripheral administration of irritants (not vesicants), document patient/provider shared decision-making and use a new PIV placed within 24 hours.
The hierarchy of hemodialysis vascular access — established by KDOQI guidelines and reinforced by “Fistula First” initiatives — prioritizes the safest and most durable access option for each patient.
An AV fistula is a direct surgical anastomosis between an artery and vein, creating a high-flow venous conduit. The radiocephalic (wrist) fistula is first choice; brachiocephalic and brachiobasilic are alternatives.
An AV graft uses synthetic material (PTFE) to connect an artery and vein. Can be cannulated earlier (2–4 weeks) than an AVF.
Used as bridge access or when AVF/AVG is not feasible. Carries the highest infection risk of any dialysis access modality.
ICU patients require simultaneous therapeutic infusion access and hemodynamic monitoring access, often through multiple concurrent devices.
Arterial catheters (A-lines) provide continuous blood pressure monitoring and facilitate frequent arterial blood gas sampling.
Site selection:
A-line maintenance:
ICU CVCs typically serve multiple functions: CVP monitoring, multiple simultaneous infusions (vasopressors, sedation, antibiotics), and blood sampling. Key points:
Patients with neutropenia (ANC <500/μL), active immunosuppression, or functional asplenia are at dramatically increased CLABSI risk. Management principles:
Complete guide to pediatric peripheral IV access: age-specific site selection (neonate to adolescent), scalp vein placement in infants, pain management (EMLA, LMX, vapocoolant, sucrose), gauge selection, restraint considerations, and family-centered care.
Comprehensive guide to oncology vascular access: port vs PICC decision-making, chemotherapy central access requirements, vesicant administration, CLABSI prevention in neutropenic patients, power-injectable port selection, and access management across the cancer treatment continuum.
Complete NICU vascular access guide: umbilical arterial and venous catheters (UAC/UVC), neonatal PICC lines, neonatal peripheral IV, gestational age considerations, skin protection, heparin-free protocols, and light protection for neonatal PN.
Clinical guide to hemodialysis vascular access: AVF creation and maturation criteria, AV graft cannulation, tunneled dialysis catheter placement and complications, vessel preservation in CKD/ESRD, fistula-first policy, buttonhole vs rope-ladder technique, and catheter-to-fistula transition.
Clinical guide to critical care vascular access: CVC site selection in the ICU, arterial line placement and management, vasopressor central access requirements, CRRT/CVVHD access, pulmonary artery catheter, CLABSI prevention in the ICU, and simultaneous multi-device management in the critically ill.